Alivus Life Sciences Reports Q1FY26 Revenue of Rs. 6,018 Mn, Gross Margins of 55.1%, and EBITDA Margins at 30.1%

Alivus Life Sciences Limited, a leading developer and manufacturer of high-value APIs, announced its financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs. 6,018 Mn, a growth of 2.2% YoY. EBITDA was at Rs. 1,813 Mn, a growth of 9.9% YoY. EBITDA margins were at 30.1%, up 210 bps YoY. PAT for the quarter stood at Rs. 1,215 Mn and PAT margins were at 20.2%. The company generated a strong free cash flow of Rs. 1,000 Mn leading to Cash and Cash Equivalents of Rs. 6,604 Mn as of June 30, 2025.